The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 1471871.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.
Medical subject headings
- Parkinson Disease
- Selegiline